
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a TechBio company, using its AI-Immunology platform to develop personalized vaccines for cancer and infectious diseases. The financial update for FY25 showed solid results, with revenues meeting expectations and a strong cash position. With a 12-month price target of $16.00 per ADS, Evaxion has a strong valuation and potential future partnerships, reflecting the potential of its innovative technology. However, investors should be cautious of risks such as clinical, regulatory, and competition in the healthcare industry.
Bears say
Evaxion is a clinical-stage TechBio company focused on developing novel vaccines with a proprietary AI platform, but their recent presentation of an off-the-shelf cancer vaccine for AML has raised concerns about the scalability and time-to-treatment of their personalized vaccine approach. This may negatively impact investor sentiment and the company's financial performance, as they push forward with their Phase 1 trial for EVX-04. Despite their commitment to transforming patients' lives, Evaxion's financials may suffer if they are unable to demonstrate the effectiveness and scalability of their platform.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares